Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Authors :: van der Schoot LS
Atalay S
Otero ME
Kievit W
van den Reek JMPA
de Jong EMGJ
Source :: The British journal of dermatology [Br J Dermatol] 2022 Dec; Vol. 187 (6), pp. 1028-1030. Date of Electronic Publication: 2022 Aug 20.
Publication Year :: 2022

Subjects :: Humans
Ustekinumab therapeutic use
Etanercept therapeutic use
Adalimumab therapeutic use
Drug Tapering
Psoriasis drug therapy
Psoriasis chemically induced
Biological Products therapeutic use

Full Text Access

Tools